ERBB2 and breast carcinoma: In breast cancer, two PARP inhibitors, olaparib and talazoparib, have been approved for treatment of gBRCAm carriers with metastatic HER2-negative breast cancer based on the OlympiAD and EMBRACA trials, respectively11,12.